The risk-adjusted, net present value (rNPV) method is the standard valuation method used within pharma and biotech companies when valuing assets beyond discovery stage. This approach depicts the drug/pipeline development plan using R&D costs & timeline, success rates, and peak sales potential. The quantity of available information in the pharmaceutical area enables to determine and benchmark those assumptions. Well-calibrated the rNPV method is thus a powerful tool to build, challenge and value the company’s strategy. It also shows how the value of the company develops along reaching milestones. Is it however enough for investors?
From an investor’s perspective, it is crucial to understand how long it takes before an exit and what is the potential for ROI (Return on Investment). They need to figure out the conditions to harvest their investment as well as to anticipate the multiple later-round investors and incentive packages to key employees that may dilute their stake.
While rNPV highlights the roadmap for the scientific bet of the company, the VC method highlights the one for the cash to be invested in.
The purpose of this workshop is to decrypt the reasons behind using rNPV or VC methodologies to value a Biotech company. With the support of interactive cases, the participants will learn more about how Biotech companies can better anticipate the VCs’ point of view when presenting their valuation work.
Thursday, 8th February 2018
24 Gewerbestrasse, Swiss Innovation Parc-Allschwil
Participation is free of charge, but seats are limited.
Registration is compulsory and subjected to validation. Priority is given to people with founded start-ups or concrete projects.
We look forward to meeting you there.
Swiss HLG would like to wish you all a very Happy New Year and we hope you enjoyed the festive season. At Swiss HLG, the celebrations are not over. Start 2018 off with a bang and join us at our Winter Conference 2018!
Just a little more than 2 weeks to go, hurry and register for our business development and networking event.
We have an impressive panel of speakers from, AZ, Actelion, Novartis, Debiopharm, Santen, Sanofi.You can look forward to engaging with an equally interesting and diverse group of senior BD&L attendees. Join us meet your peers in Roche, Novartis, Recordati, Santhera, Shire, Servier, Ferring and many more.
Join us for this exciting two and a half day program, “RESET PARTNERING – STEP OUT OF THE BOX!” where we will discuss:
How other industries, such as luxury or consumer goods, rely strongly on partnerships?
Are there new tricks to be learned from other industries, adjacent or completely separate from Life sciences?
How do Licensing, Business Development Partnering leaders peruse the right deal?
How to establish partnerships that go beyond the molecule?
“Step out of the box!”
Curious? Find out more on
“Ensuring Smooth Tech Transfer between Start-ups and Universities”
Swiss HLG in collaboration with BaselArea presented a special seminar for the 13th Start-up BaseLaunch initiative in October 2017.
Alexandra Carrel, a Swiss HLG member, presented an informative session on “How Start-ups should deal with Tech Transfer Offices.” The attendees benefitted by receiving practical tips and advice on Licensing issues in this specific and usually challenging context.The workshop explained the viewpoints from both Start-ups and Universities and gave clear strategies on how to proceed to achieve a successful negotiation.
If you are interested in further information regarding the Start-up initiative, please contact our Board Member, Zaki Sellam – email@example.com